A new lease on life—but only for those who can afford three million dollars
Two scientists, Stuart Orkin and Swee Lay Thein, have been awarded a $3 million Breakthrough Prize for decades of work that unraveled one of biology's quieter mysteries — why some bodies keep making fetal hemoglobin, and how that knowledge could silence the suffering caused by sickle cell disease and beta-thalassemia. Their discovery of BCL11A as the master switch governing hemoglobin production led directly to gene therapies now approved and showing 90% success rates. Yet the prize arrives shadowed by a familiar tension in modern medicine: a cure exists, but the world's most affected populations — millions across sub-Saharan Africa and India — remain as unreachable from it as ever, separated not by science, but by cost, complexity, and political will.
- Sickle cell disease has tormented millions for generations, warping red blood cells into shapes that block vessels and trigger days-long pain crises — and until recently, there was no cure, only endurance.
- A decades-long scientific hunt, spanning mouse experiments, seven-generation family studies in Malawi, and genome-wide searches, finally converged on a single gene — BCL11A — as the switch that silences fetal hemoglobin in adults.
- CRISPR-based therapies approved in 2023 now achieve what once seemed impossible: more than 90% of treated patients are free of pain crises or transfusion dependence, describing the outcome as a second life.
- The treatments cost up to $3 million per patient and demand intensive chemotherapy as preparation — placing them entirely beyond reach for the populations in sub-Saharan Africa and India who carry the greatest burden of the disease.
- Orkin and Thein are already working on what comes next — simpler oral small-molecule drugs that could replicate the hemoglobin switch without the cost or complexity — but the scientists themselves caution that access will require far more than scientific ingenuity.
Stuart Orkin and Swee Lay Thein received a $3 million Breakthrough Prize in April for discoveries that made it possible to functionally cure sickle cell disease and beta-thalassemia — two inherited blood disorders that have shaped, and shortened, millions of lives. The recognition was hard-won, built across decades of research into a deceptively simple observation: some people carry disease mutations yet live relatively normal lives because their bodies never stopped producing fetal hemoglobin, the form made in the womb.
Orkin, working at Harvard and Dana-Farber, began in the 1980s studying the genetics of beta-thalassemia. Thein, now at the NIH, took a different path — she noticed that some patients had inexplicably mild disease and began tracing the pattern through families, eventually assembling a multigenerational study of 210 individuals across seven generations in Malawi. In 2011, genome-wide association studies pointed to the same answer both researchers had been circling: a gene called BCL11A, previously unknown in hemoglobin biology, was the master switch controlling the transition from fetal to adult hemoglobin. Orkin's team confirmed it by disabling the gene in mice engineered with sickle cell anemia — the animals were completely corrected.
The timing aligned with the emergence of CRISPR, and by 2023, two gene therapies had received approval. Both work by editing a patient's own blood stem cells to reactivate fetal hemoglobin production. In clinical trials, more than 90% of patients experienced transformative results — sickle cell patients free of pain crises, beta-thalassemia patients no longer dependent on transfusions.
But the treatments carry a brutal price: $2 to $3 million per patient, preceded by intensive chemotherapy to clear existing bone marrow. The populations most devastated by sickle cell disease — in sub-Saharan Africa and India — have virtually no access. Thein was candid: in the near term, the answer for those patients is probably no. Both scientists are now working on next-generation approaches, including oral small molecules that could replicate the hemoglobin switch far more simply and cheaply. The prize honors what has already been achieved. What remains is the harder question of who gets to benefit from it.
Stuart Orkin and Swee Lay Thein have just won one of science's most prestigious honors—a $3 million Breakthrough Prize—for work that opened a door to curing two blood diseases that have tormented millions. The recognition arrived in April, a capstone to decades of investigation into why some people's bodies keep making fetal hemoglobin into adulthood, and how that knowledge could be weaponized against sickle cell disease and beta-thalassemia. Yet even as the prize was announced, both scientists were acutely aware of an uncomfortable truth: the treatments their discoveries enabled remain out of reach for most of the people who need them most.
Sickle cell disease is a relentless condition. The inherited disorder warps red blood cells into a sickle shape, blocking blood vessels and triggering episodes of unbearable pain that can last for days. Patients experience extreme fatigue, organ damage, and a life expectancy often cut short by decades. The disease falls heaviest on populations in sub-Saharan Africa and India, where it affects millions. For most of human history, there was no cure—only management of symptoms. Then came the discovery that changed everything.
Orkin, a pediatrics professor at Harvard Medical School and investigator at Dana-Farber Cancer Institute, began his career in the 1980s studying the genetics of beta-thalassemia, a related blood disorder caused by insufficient hemoglobin production. Early on, researchers knew something curious: people who naturally produced high levels of fetal hemoglobin—the form babies make in the womb—could live relatively normal lives despite carrying the disease mutations. The fetal version of hemoglobin works just fine in adults; it binds oxygen slightly more efficiently, but under normal circumstances, the difference is negligible. The scientific question became irresistible: could you trick an adult body into making fetal hemoglobin again?
Thein, a senior investigator at the National Institutes of Health, approached the puzzle from a different angle. She noticed that some people with beta-thalassemia had remarkably mild disease while others required blood transfusions for life. She began collecting blood samples from patients with unusually mild cases and their families. The pattern emerged: those with milder disease produced high levels of fetal hemoglobin, and this ability ran in families independently of the gene that caused the disease itself. Over more than two decades, Thein assembled a massive family study—eventually recruiting 210 individuals across seven generations from Malawi—to map which genes controlled this fetal hemoglobin production. In 2011, genome-wide association studies revealed the culprit: a gene called BCL11A, which had no previously known role in hemoglobin biology. It was the master switch.
Orkin's team confirmed the finding through elegant mouse experiments. They engineered mice with sickle cell anemia, then disabled BCL11A specifically in their developing red blood cells. The result was complete correction—the mice were healthy. One gene was sufficient. The timing proved fortuitous. Just as researchers were asking how to manipulate BCL11A in human patients, CRISPR gene-editing technology emerged, offering a precise tool to do exactly that.
The first approved therapies arrived in 2023. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia, made by bluebird bio, both work by editing a patient's own blood stem cells to either deactivate BCL11A or restore healthy hemoglobin production. In clinical trials, more than 90 percent of treated patients saw transformative results: those with sickle cell disease experienced complete resolution of their painful crises during the study period; those with beta-thalassemia no longer needed blood transfusions. Patients described it as a new lease on life.
But here is where the story darkens. The current approved therapies are extraordinarily expensive and logistically brutal. They require harvesting a patient's own stem cells, editing them in a specialized laboratory, then reinfusing them after the patient has undergone intensive chemotherapy to destroy existing bone marrow and make room for the edited cells to take hold. The entire process costs between $2 million and $3 million per patient. Even wealthy health care systems struggle to provide access. And the populations bearing the heaviest burden of sickle cell disease—in sub-Saharan Africa and India—have virtually no access at all.
Thein was direct about the gap when asked whether the people most at risk would receive these treatments soon. "Honestly, in the near term, the answer is probably not." She acknowledged that even if cheaper, simpler therapies were developed tomorrow, delivering them to patients who need them most would require political will, sustained global health investment, and a fundamental rethinking of how transformative medicines are priced and distributed. Both scientists are now pursuing next-generation approaches: Orkin's team is working on small molecules that could accomplish the same hemoglobin switch through a simple pill; Thein is focused on preventing the severe pain crises that remain one of sickle cell disease's most debilitating and undertreated aspects. The prize recognizes what they have already achieved. The real test lies ahead.
Notable Quotes
It really is transformative for these individuals. After treatment, patients describe having a new lease on life.— Stuart Orkin
The burden of sickle cell disease is heaviest in sub-Saharan Africa and India, precisely where these therapies are currently least accessible.— Swee Lay Thein
The Hearth Conversation Another angle on the story
When you discovered BCL11A, did you immediately understand you'd found the key to a therapy?
No. We found a gene that controlled fetal hemoglobin production, but understanding how to use that knowledge to treat patients took years more. The science and the medicine are different problems.
The current treatments work brilliantly in trials—90 percent success. So why can't people in Africa and India access them?
Cost is part of it, but it's deeper than that. These therapies require intensive chemotherapy, specialized labs, months of hospitalization. The infrastructure doesn't exist in most of the world. Even if we gave them away free, the logistics would be impossible.
So you're pivoting to pills instead of gene editing?
Yes. A small molecule you could take at home, that could be manufactured anywhere, distributed like any other drug. That's the only way this reaches the people who need it most.
How long until that exists?
I don't know. We're working on it. But I won't pretend this is a problem science alone can solve. It's a problem of will and resources and how we value lives in different parts of the world.
Does winning a prize change anything about that?
It brings attention. It validates the work. But the real prize would be a patient in Malawi getting treated. We're not there yet.